There are many reasons to smile in the Swedish biotech firm Hansa Biopharma these days.

The company recently announced a license agreement with US-based gene therapy firm Sarepta giving the US company license to develop the Swedish company’s main asset, imlifidase, as a potential pre-treatment for certain patients prior to gene therapy in two rare diseases.